Clinical Trial Update: Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, biodistribution, radiation dosimetry, and pharmacokinetics of BAY88-8223 in Japanese patients with prostate cancer has been comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BAY88-8223

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms | Phase 1 | Status: COMPLETED